$XOMAO News
Last published 4mo ago
- 4mo agoXOMAXOMAOXOMAPLGNDXOMA Royalty Announces Closing of Its Acquisition by LigandGlobeNewswireEMERYVILLE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation today announced that Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has completed its previously announced acquisition of XOMA Royalty.
- 5mo agoXOMAXOMAOXOMAPXOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record DateGlobeNewswireEMERYVILLE, Calif., June 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA) ("XOMA" or the "Company") today announced that its Board of Directors has authorized the following cash dividends to holders
- 8mo agoXOMAXOMAOXOMAPXOMA Royalty to Present at Investor Conferences in MarchGlobeNewswireEMERYVILLE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following investor
- 9mo agoGBIOXOMAXOMAOXOMAPXOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc.GlobeNewswireEMERYVILLE, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA) ("XOMA Royalty" or the "Company"), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies
- 10mo agoXOMAXOMAOXOMAPXOMA Royalty Announces CFO TransitionGlobeNewswireEMERYVILLE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) announced today its Chief Financial Officer, Thomas Burns, will be stepping down from his position with XOMA
- 10mo agoXOMAXOMAOXOMAPXOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for MezagitamabGlobeNewswire– Takeda regains a majority of XOMA Royalty's royalty interest in mezagitamab (TAK-079) –– XOMA Royalty will be entitled to payments based on a share of milestones and royalties associated with nine development-stage
- 10mo agoXOMAXOMAOXOMAPXOMA Royalty Declares Quarterly Preferred Stock DividendsGlobeNewswireEMERYVILLE, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA), the biotech royalty aggregator, today announced its Board of Directors has authorized the following cash dividends to
- 11mo agoMURAXOMAXOMAOXOMAPXOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plcGlobeNewswireEMERYVILLE, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA), the biotech royalty aggregator, today announced it has successfully completed its previously announced
- 11mo agoLVTXXOMAXOMAOXOMAPXOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.GlobeNewswireEMERYVILLE, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) today announced it has successfully completed its previously announced acquisition of all the outstanding
- 12mo agoXOMAXOMAOXOMAPXOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business AchievementsGlobeNewswireBusiness development: Secures royalty economic interests in two early stage partnered assets through XOMA Royalty's announced expected acquisition of LAVA Therapeutics. Company acquisitions: •Completed XOMA Royalty's
- 1y agoLVTXXOMAXOMAOXOMAPXOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase AgreementGlobeNewswire- Amendment includes finalized cash amount and updated CVR terms for tender offer - LAVA announces new date for extraordinary general meeting of shareholders EMERYVILLE, Calif. and UTRECHT, The Netherlands and
- 1y agoLVTXXOMAXOMAOXOMAPXOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.GlobeNewswireEMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Oct. 02, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) and LAVA Therapeutics N.V. ("LAVA") (NASDAQ:LVTX) today
- 1y agoXOMAXOMAOXOMAPXOMA Royalty Declares Quarterly Preferred Stock DividendsGlobeNewswireEMERYVILLE, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty's Series A and
- 1y agoHLVXXOMAXOMAOXOMAPXOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc.GlobeNewswireEMERYVILLE, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA) ("XOMA Royalty" or the "Company"), a biotechnology royalty aggregator playing a distinctive role in helping biotech
- 1y agoXOMAXOMAOXOMAPXOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewswireEMERYVILLE, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today its Chief Executive Officer, Owen Hughes, and Chief Investment Officer,
- 1y agoXOMAXOMAOXOMAPXOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business AchievementsGlobeNewswireBusiness development: Purchased mezagitamab royalty and milestone rights held by BioInvent International and will secure royalty economic interests in two early-stage partnered assets through XOMA Royalty's recently
- 1y agoTSBXXOMAXOMAOXOMAPXOMA Royalty Announces Closing of Tender Offer for Turnstone BiologicsGlobeNewswire- Turnstone Stockholders Received $0.34 Per Share in Cash Plus Contingent Value Right - EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA) ("XOMA Royalty" or the "Company"), a
- 1y agoLVTXXOMAXOMAOXOMAPXOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value RightGlobeNewswireEMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) and LAVA Therapeutics N.V. ("LAVA") (NASDAQ:LVTX) announced
- 1y agoHLVXXOMAXOMAOXOMAPHilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value RightGlobeNewswireBOSTON and EMERYVILLE, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX) and XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) announced today they have entered
- 1y agoTSBXXOMAXOMAOXOMAPTurnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value RightGlobeNewswireEMERYVILLE, Calif. and SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) and Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX) today announced
- 1y agoXOMAXOMAOXOMAPXOMA Royalty Declares Quarterly Preferred Stock DividendsGlobeNewswireEMERYVILLE, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty's Series A and
- 1y agoXOMAXOMAOXOMAPXOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 MillionGlobeNewswireEMERYVILLE, Calif. and LUND, Sweden, May 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA), the biotech royalty aggregator, and BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a
- 1y agoXOMAXOMAOXOMAPXOMA Royalty Reports First Quarter 2025 Financial Results and Highlights Business AchievementsGlobeNewswirePipeline advancements: The Marketing Authorization Application (MAA) for Day One Biopharmaceuticals and Ipsen's tovorafenib was accepted for review by the European Marketing Authority (EMA) and Takeda initiated its Phase
- 1y agoXOMAXOMAOXOMAPXOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual ConferenceGlobeNewswireEMERYVILLE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today its Chief Executive Officer, Owen Hughes, and Chief Investment Officer, Brad
- 1y agoXOMAXOMAOXOMAPXOMA Royalty Completes Sale of Kinnate Pipeline AssetsGlobeNewswireXOMA Royalty sold the remaining Kinnate pipeline assets for a total of up to $270 million in upfront and milestone payments, plus royalties on commercial sales at rates ranging from low single digits to mid-teens
- 1y agoXOMAXOMAOXOMAPXOMA Royalty to Present at Jones Healthcare and Technology Innovation ConferenceGlobeNewswireEMERYVILLE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (("XOMA", NASDAQ:XOMA), the biotech royalty aggregator, announced today Chief Investment Officer, Brad Sitko, will be a featured presenter
- 1y agoXOMAXOMAOXOMAPXOMA Royalty Declares Quarterly Preferred Stock DividendsGlobeNewswireEMERYVILLE, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty's Series A and
- 1y agoXOMAXOMAOXOMAPXOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business AchievementsGlobeNewswireDoubled the royalty and milestone portfolio to over 120 royalty assets with significant milestone potential through five transactions in 2024 Completed two whole company acquisitions to unlock shareholder value Day
- 1y agoXOMAXOMAOXOMAPXOMA Royalty to Present at Investor Conferences in MarchGlobeNewswireEMERYVILLE, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following investor
- 1y agoXOMAXOMAOXOMAPXOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences ConferenceGlobeNewswireEMERYVILLE, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the Oppenheimer 35th
- 1y agoXOMAXOMAOXOMAPXOMA Royalty Declares Quarterly Preferred Stock DividendsGlobeNewswireEMERYVILLE, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA's Series A and Series
- 1y agoXOMAXOMAOXOMAPXOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its PortfolioGlobeNewswireSeralutinib becomes XOMA Royalty's seventh Phase 3 royalty asset, further building the late-stage pipeline beyond its six current commercial royalty assets Seralutinib is being developed and co-commercialized by
- 2y agoXOMAXOMAOXOMAPXOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent ActivitiesGlobeNewswireZevra's MIPLYFFA™ (arimoclomol) received FDA approval and became the sixth commercial asset in XOMA Royalty's portfolio XOMA Royalty acquired a 50 percent economic interest in TWIST Bioscience's portfolio of
- 2y agoXOMAXOMAOXOMAPXOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist BioscienceGlobeNewswireXOMA Royalty has acquired 50 percent of Twist's existing royalty and milestone economics for $15 million XOMA Royalty's portfolio now holds over 100 assets ranging from revenue-generating commercial therapeutics to
- 2y agoXOMAXOMAOXOMAPZevra's MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)GlobeNewswireMIPLYFFA™ is the first therapy approved for use in patients with NPC, a rare genetic disorder XOMA Royalty is entitled to receive a mid-single digit royalty on MIPLYFFA™ sales and up to $52.6 million in
- 2y agoXOMAXOMAOXOMAPXOMA Royalty Declares Quarterly Preferred Stock DividendsGlobeNewswireEMERYVILLE, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA) ("XOMA" or the "Company") today announced its Board of Directors has authorized the following cash dividends to holders of
- 2y agoXOMAXOMAOXOMAPXOMA Royalty to Present at Upcoming Investor Conferences in SeptemberGlobeNewswireEMERYVILLE, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following September
- 2y agoXOMAXOMAOXOMAPXOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent ActivitiesGlobeNewswireCash receipts totaled $22.6 million in 2Q24, inclusive of royalty income and milestones from Day One Pharmaceuticals and Rezolute Expanded the commercial royalty and milestone portfolio with the acquisition
- 2y agoXOMAXOMAOXOMAPXOMA Declares Quarterly Preferred Stock DividendsGlobeNewswireEMERYVILLE, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA) ("XOMA" or the "Company") today announced its Board of Directors has authorized the following cash dividends to holders of XOMA's
- 2y agoXOMAXOMAOXOMAPXOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals' Sale of its Priority Review VoucherGlobeNewswireEMERYVILLE, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today it has received an $8.1 million milestone payment from Viracta Therapeutics, Inc.,
- 2y agoXOMAXOMAOXOMAPXOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQGlobeNewswireEMERYVILLE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today that members of its Executive Team will participate in the H.C. Wainwright 2nd Annual
- 2y agoXOMAXOMAOXOMAPXOMA Reports First Quarter 2024 Financial Results and Highlights Recent ActivitiesGlobeNewswireEarned $9 million milestone upon U.S. Food and Drug Administration's approval of Day One's OJEMDA™ (tovorafenib); XOMA is entitled to receive a mid-single digit royalty on OJEMDA™ sales Acquired Kinnate
- 2y agoXOMAXOMAOXOMAPXOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%GlobeNewswireOrganon, a global women's healthcare company, initiated XACIATO™ commercial activities in the fourth quarter of 2023 XOMA further expands its late-stage portfolio with synthetic royalty and milestone interests in
- 2y agoXOMAXOMAOXOMAPXOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One's OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)GlobeNewswireXOMA is entitled to a mid-single digit royalty on global OJEMDA™ sales First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or
- 2y agoKNTEXOMAXOMAOXOMAPXOMA Corporation Announces Closing of Tender OfferGlobeNewswireEMERYVILLE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA) ("XOMA" or the "Company"), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their
- 2y agoXOMAXOMAOXOMAPXOMA Declares Quarterly Preferred Stock DividendsGlobeNewswireEMERYVILLE, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA) ("XOMA" or the "Company") today announced its Board of Directors has authorized the following cash dividends to holders of XOMA's
- 2y agoKNTEXOMAXOMAOXOMAPXOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.GlobeNewswireEMERYVILLE, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- As previously announced on February 16, 2024, XOMA Corporation (("XOMA" or the "Company", NASDAQ:XOMA) entered into a merger agreement to acquire Kinnate Biopharma
- 2y agoXOMAXOMAOXOMAPXOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder ValueGlobeNewswireRaised up to $140 million of non-dilutive non-recourse capital through a royalty-backed loan related to VABYSMO® from funds managed by Blue Owl Capital Received $15.5 million in cash payments related to our growing
- 2y agoXOMAXOMAOXOMAPXOMA to Present at Upcoming Investor Conferences in MarchGlobeNewswireEMERYVILLE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following March 2024 investor
- 2y agoKNTEXOMAXOMAOXOMAPXOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value RightGlobeNewswireEMERYVILLE, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA) announced today it has entered an agreement to acquire Kinnate Biopharma Inc. (NASDAQ:KNTE) for (i) a base cash price of $2.3352 per